Kallisio

Executive Summary

Kallisio is a San Diego-based medical technology company pioneering personalized oral-cavity solutions for targeted drug delivery and radiotherapy precision. Its flagship product, Stentra™, is a custom 3D-printed immobilization device designed to enhance accuracy in radiation therapy for head and neck cancer. By combining advanced design automation and rapid manufacturing, Kallisio addresses a critical unmet need: reducing damage to healthy tissue while improving treatment efficacy. The platform’s scalability positions it to transform standard-of-care in oncology, appealing to hospitals seeking to minimize side effects and improve patient outcomes. As an early-stage private company founded in 2017, Kallisio has not disclosed funding rounds or revenue, but its technology aligns with growing trends toward personalized medicine and cost-effective, patient-specific devices. The head and neck cancer radiotherapy market, valued at over $2 billion, represents a significant opportunity. Kallisio’s ability to secure regulatory approvals, forge partnerships with cancer centers, and demonstrate clinical utility will be key to its growth. With a focused product pipeline and a clear value proposition, the company is positioned for gradual adoption, though commercialization risks remain in the competitive medtech landscape.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance or breakthrough device designation for Stentra™70% success
• Q3 2026Clinical partnership with a major cancer center for validation studies65% success
• Q1 2027Series A or B funding round to scale manufacturing and commercialization50% success